| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C12H9N3O5 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Nifuroxazide is an effective inhibitor of STAT3 that also exerts potent anti-tumor and anti-metastasis activity. It is an orally active nitrofuran antibiotic. It is supplied as a light yellow to yellow solid (C12H9N3O5, MW 275.22) at 99.90% purity.
Physical & Chemical Properties
| CAS Number | 965-52-6 |
|---|---|
| Molecular Formula | C12H9N3O5 |
| Molecular Weight | 275.22 g/mol |
| Purity | 99.90% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2 |
| Target | STAT3 |
| Signaling Pathway | JAK/STAT Signaling; Stem Cell/Wnt; Anti-infection |
| Solubility | In Vitro: DMSO: ≥ 155 mg/mL (563.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 155 mg/mL (563.19 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.58 mg/mL (9.37 mM); suspension |
| How to prepare | Gives a suspension at ≥ 2.58 mg/mL (saturation not determined). The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (25.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.58 mg/mL (9.37 mM); suspension |
| How to prepare | Gives a suspension at ≥ 2.58 mg/mL (saturation not determined). The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (25.8 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Incubating U266 cells with Nifuroxazide produces a significant, dose-dependent drop in STAT3 tyrosine phosphorylation. This loss of STAT3 tyrosine phosphorylation is rapid, appearing as early as 1 h after treatment, and persists for at least 24 h. Exposing U266 or INA6 cells to Nifuroxazide for 48 hours leads to a dose-dependent loss of cell viability, with an EC50 of approximately 4.5 μM in both cell types. MM cells without constitutive STAT3 activation, in contrast, show little toxicity from Nifuroxazide[1].
In Vivo
Relative to the vehicle group, Nifuroxazide treatment inhibits tumor growth and tumor weight in a dose-dependent manner, with tumor volume inhibition rates of 43.0% at 25 mg/kg and 62.1% at 50 mg/kg. Nifuroxazide also significantly reduces the proliferation of nuclear Ki-67-positive cells and induces apoptosis in cleaved caspase-3-positive cells. In A375 tumor tissues, Nifuroxazide treatment lowers the expression of MMP-2, MMP-9, and p-Stat3. In the B16-F10 melanoma metastasis model, Nifuroxazide also blocks MDSC infiltration into the lung, which might be linked to suppressed distant colonization by tumor cells[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Animal Administration[2]
Mice[2] Engraft 1×107 A375 cells subcutaneously into mice, randomize the animals into groups once tumor volume reaches around 100 mm3, and administer Nifuroxazide 25 mg/kg, 50 mg/kg, or vehicle by intraperitoneal injection once daily. Measure tumor size and body weight every 3 days. Engraft C57Bl/6J mice with 2×105 B16-F10 cells by intravenous tail-vein injection to produce experimental lung metastasis. Randomize the mice into groups on day 6 and inject Nifuroxazide 50 mg/kg or vehicle intraperitoneally once daily. Count the black dots on the lung surface and confirm them as melanoma metastases[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
L3MBTL3 and STAT3 collaboratively upregulate SNAIL expression to promote metastasis in female breast cancer. Nat Commun 2025 Jan 2;16(1):231. PMID: 39747894
RBM24 regulates phenotypic switching of smooth muscle cell in vascular remodeling by stabilizing JAK2 mRNA. Cardiovasc Res 2025 Nov 11:cvaf219. PMID: 41216933
Chondroitin sulfate-functionalized GSH-responsive lipid-nanoparticle inhibits melanoma metastasis through suppressing STAT3 activation. Int J Pharm 2026 May 15:126989. PMID: 42142674
Target antifungal peptides of immune signalling pathways in silkworm, Bombyx mori, against Beauveria bassiana. Insect Mol Biol 2021 Feb;30(1):102-112. PMID: 33150694
Res Sq. 2026 Jan 9.
